Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments

Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory ... Read More